by The gastric motility disorder drug market comprises drugs that are used for the treatment of various gastrointestinal motility disorders such as gastric motility disorder, gastric stasis, gastroparesis, and others. Drugs used for the treatment of these disorders include proton pump inhibitors, ghrelin receptor agonists, motilin receptor agonists, cholinergic receptor agonists, and others. The rising prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), intestinal motility disorders, and gastric stasis coupled with large unmet treatment needs has increased the demand for effective drugs. The Global gastric motility disorder drug market is estimated to be valued at US$ 57.65 Bn in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the gastric motility disorder drug market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals. The key players are mainly focused on developing advanced drug formulations and drug candidates for treatment-resistant gastrointestinal motility disorders through organic and inorganic growth strategies such as mergers, acquisitions, and collaborations.
Gastric motility disorder drug market size provides significant growth opportunities for market players in developing countries owing to increasing awareness. Companies are focused on developing novel drug formulations to expand their presence in emerging Asian and Latin American markets. For instance, Endo Pharmaceuticals is focused on expanding its business operations in Asian countries like Japan, China, and South Korea.
The rising global burden of gastrointestinal disorders and lack of effective treatment options indicate considerable opportunities for gastric motility disorder drug market players. The demand is especially higher in Asia Pacific and Middle Eastern countries. However, high development costs and regulatory hurdles associated with developing the novel class of gastrointestinal drugs are major challenges for sustainable growth in these regional markets.
Market Drivers
The key driver contributing to the growth of gastric motility disorder drug market includes the rising geriatric population and changing lifestyle patterns. As aging enhances the risks of gastrointestinal dysfunctions and motility disorders, the growing geriatric population globally is increasing the patient pool. According to WHO, the global population aged 60 years and older is expected to reach 2 billion by 2050 from 962 million in 2017. Additionally, changing dietary patterns and lack of physical activity increase the chances of gastrointestinal diseases requiring motility drugs. The high prevalence of underlying disorders leading to gastric motility issues also presents growth opportunities for market players. However, safety issues associated with long-term consumption and lack of novel treatments are hindering the market growth.
PEST Analysis
Political: Regulations set by food and drug administration authorities across different countries on clinical trials and drug approvals can impact the development and commercialization of drugs for gastric motility disorders. Variations in regulations pose challenges.
Economic: Economic performance of key markets affects healthcare spending and thereby demand for gastric motility disorder drugs. Economic recessions may negatively impact sales. Prices and insurance coverage play a role too.
Social: Rising awareness about lifestyle diseases, aging populations, and digestive disorders increases social acceptance and demand for effective treatment options. Social stigma around certain gastric issues can hamper patients seeking timely treatment.
Technological: Advancements in drug delivery mechanisms, formulation research, and clinical study methodologies aid the development of novel therapies. Molecular level understanding of disease pathways enables targeted drugs. However, high development costs pose barriers.
The United States accounts for the largest share of Gastric Motility Disorder Drug Market Regional Analysis in terms of value owing to high healthcare spending as well as presence of leading pharmaceutical companies. Europe is another major geographical region concentrated for this market supported by favorable public insurance schemes in various countries.
Asia Pacific region is poised to experience the fastest growth in the gastric motility disorder drug market during the forecast period. Factors such as rising healthcare expenditure, increasing prevalence of gastric issues due to changing dietary patterns and lifestyles, growing medical tourism, and strengthened regulatory frameworks will support higher investments towards gastrointestinal drugs market in emerging Asian countries.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals.